Objective  To investigate the clinical applicability of the Clinical Pathway for Short Stature (2019 Edition).

Methods A cross-sectional survey was conducted among pediatric endocrinologists using a questionnaire adapted from the guideline clinical applicability evaluation tool. Descriptive analysis was performed on the basic characteristics of respondents, dimensional scores, pathways of access, and factors influencing implementation. Kruskal-Wallis rank-sum test and Nemenyi test were used for multiple and pairwise comparisons. Multiple linear regression analysis combined with stepwise regression was used to analyze factors influencing the scores.

Results  A total of 206 valid questionnaires were collected. The mean and median scores for all dimensions and overall evaluation of the clinical pathway for short stature were ≤75 points. The median scores for acceptability, readability, feasibility, accessibility, and overall evaluation were 75.00, 62.50, 62.50, 50.00, and 75.00, respectively. Eighteen percent of the survey respondents believed that there were implementation barriers to the clinical pathway, including factors related to medical staff, patients, the environment, and the clinical pathway itself. Multiple comparisons and multiple linear regression analysis showed that familiarity with the clinical pathway was the main influencing factor for the scores (P<0.05).

Conclusion There is significant room for improvement in the applicability of the clinical pathway for short stature in China. Efforts in promoting, training, and disseminating the clinical pathway need to be enhanced, and implementation requires stronger support in terms of environment and technology.

1.胡亚美, 江载芳. 诸福棠实用儿科学, 第7版[M]. 北京: 人民卫生出版社, 2002. [Hu YM, Jiang ZF. Zhu Futang's Practical Pediatrics, 7th edtion[M]. Beijing: People's Medical Publishing House, 2002.]

2.Li F, Liu K, Zhao Q, et al. Prevalence of short stature among children in China: a systematic review[J]. Pediatr Investig, 2021, 5(2): 140-147. DOI: 10.1002/ped4.12233.

3.Zhao Q, Zhang M, Chu Y, et al. A retrospective analysis of patients with short stature in eastern China between 2013 and 2019[J]. Biomed Res Int, 2021, 2021: 6640026. DOI: 10.1155/2021/6640026.

4.Wu S, Liu QQ, Gu W, et al. A retrospective analysis of patients with short stature in the south of China between 2007 and 2015[J]. Biomed Res Int, 2018, 2018: 5732694. DOI: 10.1155/2018/5732694.

5.梁雁, 罗小平. 高度重视重组人生长激素在儿科临床的规范化应用及安全性监测[J]. 中华儿科杂志, 2013, 51(6): 401-405. [Liang Y, Luo XP. Paying high attention to the standardized application and safety monitoring of recombinant human growth hormone in pediatric clinical practice[J]. Chinese Journal of Pediatrics, 2013, 51(6): 401-405.] DOI: 10.3760/cma.j.issn.0578-1310.2013.06.001.

6.冯佳佳, 林丽开. 我国临床诊疗规范体系建设的现状和建议 [J]. 中国研究型医院, 2018, 5(6): 37-41. [Feng JJ, Lin  LK. Current status and suggestion on the construction of clinical diagnosis and treatment standard system in China[J]. Journal of Chinese Research Hospitals, 2018, 5(6): 37-41.] DOI: 10.19450/j.cnki.jcrh.2018.06.008.

7.Rotter T, Kinsman L, James E, et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs[J]. Cochrane Database Syst Rev, 2010, 3(3): CD006632. DOI: 10.1002/14651858.CD006632.pub2.

8.国家卫生健康委. 国家卫生健康委办公厅关于印发有关病种临床路径(2019年版)的通知. (2019-12-29) [2023-07-03]. https://www.cn-healthcare.com/article/20200103/content-528299.html

9.Tabachnick BG, Fidell LS. Using multivariate statistics, 7th edtion[M]. New York: Pearson Education, Inc, 2019.

10.Sharma A, Minh Duc NT, Luu Lam Thang T, et al. A consensus-based checklist for reporting of survey studies (CROSS)[J]. J Gen Intern Med, 2021, 36(10): 3179-3187. DOI: 10.1007/s11606-021-06737-1.

11.李海龙,张川,黄超,等. 指南临床适用性评价工具信效度分析[J]. 中国循证医学杂志, 2020, 20(4): 378-382. [Li  HL, Zhang C, Huang C, et al. Reliability and validity analysis of guideline clinical applicability evaluation tools[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(4): 378-382.] DOI: 10.7507/1672-2531.201909124.

12.张川,李海龙,黄超,等. 指南临床适用性评价实证研究: 以肾移植指南临床适用性评价为例[J]. 中国循证医学杂志, 2020, 20(5): 543-550. [Zhang C, Li HL, Huang C, et al. An empirical study on evaluation of clinical applicability of kidney transplantation guideline[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(5): 543-550.] DOI: 10.7507/1672-2531.201909125.

13.黄超,李海龙,张川,等. 指南临床适用性评价实证研究: 以糖尿病指南临床适用性评价为例[J]. 中国循证医学杂志, 2020, 20(5): 536-542. [Huang C, Li HL, Zhang C, et al. An empirical study on the evaluation of the clinical applicability of the guideline for diabetes[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(5): 536-542.] DOI: 10.7507/1672-2531.201909126.

14.靳英辉,赵志慧,黄粲然,等. 临床实践指南实施性评价工具的研制和验证评价[J]. 中国循证医学杂志, 2022, 22(1): 111-119. [Jin YH, Zhao ZH, Huang CR, et al. Development and validation for evaluation of an evaluation tool for guideline implementation[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(1): 111-119.] DOI: 10.7507/1672-2531.202106002.

15.Curran Paul G. Methods for the detection of carelessly invalid responses in survey data[J]. J Exp Soc Psychol, 2016, 66(1): 4-19. DOI: 10.1016/j.jesp.2015.07.006.

16.马利,熊珊,张磊,等. 推动临床路径管理的影响因素及对策分析[J]. 现代医院管理, 2024, 22(3): 85-88. [Ma L, Xiong S, Zhang L, et al. Analysis of the influencing factors and countermeasures for promoting clinical pathway management[J]. Modern Hospital Management, 2024, 22(3): 85-88.] DOI: 10.3969/j.issn.1672-4232.2024.03.024.

17.李雯燕,曾力楠,李思雨,等. 中国儿童临床指南现状分析及循证临床指南质量评价[J]. 中国循证医学杂志, 2021, 21(12): 1450-1456. [Li WY, Zeng LN, Li SY, et al. Analysis on status of clinical guidelines and evaluation of evidence-based clinical guidelines for children in China[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21(12): 1450-1456.] DOI: 10.7507/1672-2531.202108191.

18.姚海波,强梅. 矮小身材儿童预防性筛查和临床治疗路径管理方案的探索[J]. 中国校医, 2017, 31(2): 87-89, 91. [Yao HB, Qiang M. Study on administrative pathway combining preventive screening and clinical practice for short stature children[J]. Chinese Journal of School Doctor, 2017, 31(2): 87-89, 91.] DOI: CNKI:SUN:XIYI.0.2017-02-004.

19.中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6): 428-430. [Endocrinology, Genetics, and Metabolism Group of the Chinese Medical Association Science Branch. Guidelines for diagnosis and treatment of children with short stature[J]. Chinese Journal of Pediatrics, 2008, 46(6): 428-430.] DOI: 10.3321/j.issn:0578- 1310.2008.06.007.

20.林珂雯,娄佳奡,彭淑桢,等. 临床路径的制订与管理系列研究之二: 临床路径的信息化管理[J]. 医学新知, 2024, 34(3): 322-329. [Lin KW, Lou JA, Peng SZ, et al. Research on the development and management of clinical pathways Ⅱ: information management of clinical pathways[J]. Yixue Xinzhi Zazhi, 2024, 34(3): 322-329.] DOI: 10.12173/j.issn.1004-5511.202311094.

21.王丹,陈治水,张良辉,等. 临床路径实施中医务人员满意度调查及影响因素分析[J]. 中国医院管理, 2014, 34(1): 31-33. [Wang D, Chen ZS, Zhang LH, et al. Analysis of medical workers' satisfaction and influencing factors with the implementation of clinical pathway[J]. Chinese Hospital Management, 2014, 34(1): 31-33.] DOI: CNKI:SUN:YYGL.0.2014-01-017.